5840
J. Qi et al. / Tetrahedron 56 (2000) 5835±5841
The dried fruiting bodies (4.30 kg) of the mushroom were
powdered and immersed in EtOH with occasional stirring
for 10 days. The mixture was ®ltered and the ®ltrate was
concentrated to produce an EtOH extract (593.3 g) as a
viscous brown oil, which was divided into three portions
and subjected to solvent partition. In a typical case, a portion
(209.7 g) of the extract was dissolved in 90% aq. MeOH
(1 liter) and washed twice with hexane (0.8 l). The aq.
MeOH layer was concentrated, dissolved in H2O (0.8 l),
and then extracted three times with BuOH (0.4 l). The
BuOH fractions from the three portions were combined
and concentrated to give a yellowish viscous oil (74.9 g),
which was chromatographed on ODS (Cosmosil 75 C18-
OPN, 350 g, Nacalai Tesque) eluted with MeOH/H2O
(90:10, 95:5) and then MeOH to give four fractions. The
active third fraction (9.9 g), which was eluted with MeOH/
H2O (95:5), was separated by a silica gel (Silica gel 60 230±
240 Mesh ASTM, 150 g, Merck) open column eluted with
CHCl3/MeOH (95:5, 90:10) and MeOH to give four frac-
tions. The active third fraction (249 mg), which was eluted
with CHCl3/MeOH (90:10), was suspended in 90% aqueous
MeOH (12 ml) and ®ltered through a ®lter (DISMIC-13HP,
0.45 mm, Toyo Roshi). The ®ltrate (220 mg) was subjected
to HPLC [Develosil ODS-10 (f 20/250 mm), ¯ow rate:
8 ml/min; 4 injections] eluted by MeOH/H2O (90:10) to
yield termitomycesphins A (1) (11.5 mg, tR93 min),
crude B (2) (25.0 mg, tR162 min), C (3) (11.9 mg,
tR100 min), D (4) (24.6 mg, tR173 min). The pure
sample of 2 (13.0 mg, tR250 min) was obtained from the
crude sample (20 mg) by further HPLC [Develosil ODS-10
(f 20/250), ¯ow rate: 8 ml/min] eluted by CH3CN/H2O
(82:18).
derivative 5: colorless powder, FABMS m/z 798 (M1Na)1,
1H NMR (pyridine-d5, 400 MHz) d 8.42 (1H, d, J8.4 Hz,
NH), 5.46 to 7.66 (broad singlets or doublets, seven OH),
4.90 (1H, d, J7.7 Hz, H-100), 4.71 (1H, m, H-2), 4.69 (1H,
m, H-3), 4.67 (1H, m, H-1b), 4.59 (1H, m, H-20), 4.52 (1H,
d, J11.4 Hz, H-600b), 4.36 (1H, dd, J11.4, 5.5 Hz,
H-600a), 4.23 (1H, m, H-1a), 4.20 (1H, m, H-400), 4.18 (1H,
m, H-300), 4.02 (1H, dd, J7.7, 7.2 Hz, H-200), 3.91 (1H, m,
H-500), 3.77/3.67 (1H, m, H-8, 1:1 ratio), 2.21 (1H, m,
H-30b), 2.05 (1H, m, H-30a), 1.63 to 1.90 (m, methylenes),
1.25 (s, methylenes), 1.09/1.07 (3H, d, J7.4 Hz, H-19, 1:1
ratio), 0.86 (3H, t, J6.1 Hz, terminal methyl), 0.85 (3H, t,
J6.9 Hz, terminal methyl).
A solution of 5 (4.6 mg) in a mixture of MeOH (1 ml), water
(0.1 ml), and 12 N HCl (0.1 ml) was re¯uxed for 7 h. The
reaction mixture was cooled and dried by a N2 ¯ow. The
residue was dissolved in MeOH/H2O (90:10) (4 ml) and
extracted three times with hexane (4 ml). The hexane layers
were combined, concentrated, and puri®ed by preparative
TLC (silica gel, EtOAc/hexane1:3, Rf0.44) to afford the
fatty acid methyl ester 6 (1.3 mg): colorless powder,
[a]D2524.4 (c 0.092, CHCl3) [lit.8 [a]D2423.6 (CHCl3)],
1
FABMS m/z 315 (M1H)1, H NMR (CDCl3, 400 MHz) d
4.19 (1H, m, H-2), 3.79 (3H, s, COOCH3), 2.66 (1H, d,
J5.8 Hz, OH), 1.78 (1H, m, H-3), 1.63 (1H, m, H-3),
1.26 (30H, br s, methylenes), d 0.88 (3H, t, J6.8 Hz,
terminal methyl).
The aqueous methanolic layer was concentrated, dissolved
in MeOH (0.2 ml), and neutralized by passing through an
Amberlite CG-4B (OH- form) resin column (3 ml), which
was then eluted with MeOH (20 ml). The eluate was
concentrated, dissolved in H2O (2 ml), and extracted twice
with EtOAc (2 ml). The aqueous phase was puri®ed by TLC
(silica gel, CHCl3/MeOH4:1, developed twice, Rf0.36)
to afford a mixture of methyl a- and b-d-glucopyranoside
(2:1): [a]2D4175 (c 0.035, MeOH) [lit.7 [a]2D5177.3 (c
0.1, MeOH)].
Termitomycesphin A (1). A colorless powder; [a]2D416.0
(c 0.233, MeOH); IR (KBr) 3386, 2922, 2853, 1648, 1537,
1467, and 1078 cm21; HRESIMS m/z 744.5621, calcd for
1
C41H78NO10 (M1H) 744.5626, for H and 13C NMR see
Table 1.
Termitomycesphin B (2). A colorless powder; [a]2D416.6
(c 0.119, MeOH); IR (KBr) 3390, 2923, 2853, 1648, 1535,
1467, and 1078 cm21; HRESIMS m/z 772.5937, calcd for
C43H82NO10 (M1H) 772.5939; 1H and 13C NMR were
superimposable on those of 1 (Table 1).
The EtOAc phase was concentrated and benzoylated with
benzoyl chloride (30 ml) and DMAP (1 mg) by stirring in
dry pyridine (1.5 ml) for 5 h at 508C. The reaction was
quenched by adding H2O (0.5 ml) and stirring for 5 min.
The reaction mixture was concentrated in vacuo, dissolved
in benzene (1 ml), and passed through an alumina (7 g)
column (Aluminiumoxid 90, II±III, Merck). The column
was eluted with hexane/EtOAc (9:1 and then 8:2), and the
combined eluates were concentrated and puri®ed by
preparative TLC (silica gel, EtOAc/hexane1:9, developed
two times, Rf0.18) to afford (2S,3R)-2-benzoylamido-
1,3,8-tribenzoyloxy-9-methyloctadecane (8) (0.6 mg) as a
colorless powder: 1H NMR (400 MHz, CDCl3) d 8.02
(4H, m), 7.94 (2H, m), 7.77 (2H, m), 7.34±7.55 (12H, m),
7.08/7.06 (1H, d, J8.5 Hz, 1:1 ratio), 5.36 (1H, m), 5.07/
5.03 (1H, m, 1:1 ratio), 4.85 (1H, m), 4.63 (1H, m), 4.58
(1H, m), 1.22±1.94 (25H, m), and 0.84±0.96 (6H, m).
Termitomycesphin C (3). A colorless powder; [a]2D417.6
(c 0.226, MeOH); IR (KBr) 3387, 2927, 2854, 1637, 1541,
1467, and 1079 cm21; HRFABMS m/z 766.5421, calcd for
C41H77NO10Na (M1Na) 766.5445; for 1H and 13C NMR see
Table 1.
Termitomycesphin D (4). A colorless powder; [a]2D418.0
(c 0.400, MeOH); IR (KBr) 3375, 2924, 2854, 1646, 1540,
1467, and 1079 cm21; HRFABMS m/z 794.5753, calcd for
1
C43H81NO10Na (M1Na) 794.5759; H and 13C NMR were
superimposable on those of 3 (Table 1).
Degradation of 2
Degradation of 4
A solution of 2 (4.6 mg) in EtOH (1 ml) was stirred in the
presence of PtO2 (1 mg) under hydrogen atmosphere for 4 h
at room temperature. The reaction mixture was ®ltered, and
the ®ltrate was concentrated to afford 4.6 mg of tetrahydro
Termitomycesphin D (4) (6 mg) was subjected to
hydrogenation followed by acidic methanolysis in the
same conditions as those for 2, yielding methyl a- and